{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:39:23Z","timestamp":1762987163326,"version":"3.45.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jtocrr.2020.100017","type":"journal-article","created":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T02:42:24Z","timestamp":1582339344000},"page":"100017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8995-019X","authenticated-orcid":false,"given":"Saro","family":"Kasparian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar","family":"Gentille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric H.","family":"Bernicker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2020.100017_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1200\/EDBK_200643","article-title":"Patterns of response and progression to immunotherapy","volume":"38","author":"Borcoman","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jtocrr.2020.100017_bib2","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/cncr.31997","article-title":"Hyperprogression with immunotherapy: is it real?","volume":"125","author":"Popat","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.jtocrr.2020.100017_bib3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtocrr.2020.100017_bib4","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2020.100017_bib5","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/cncr.31999","article-title":"Hyperprogressive disease in early-phase immunotherapy trials: clinical predictors and association with immune-related toxicities","volume":"125","author":"Kanjanapan","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.jtocrr.2020.100017_bib6","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/annonc\/mdx178","article-title":"Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"28","author":"Sa\u00e2da-bouzid","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2020.100017_bib7","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1001\/jamaoncol.2018.3676","article-title":"Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy","volume":"4","author":"Ferrara","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtocrr.2020.100017_bib8","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","article-title":"Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2020.100017_bib9","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2217\/fon-2018-0882","article-title":"Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data","volume":"15","author":"Valle","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.jtocrr.2020.100017_bib10","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41571-018-0111-2","article-title":"Hyperprogressive disease: recognizing a novel pattern to improve patient management","volume":"15","author":"Champiat","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtocrr.2020.100017_bib11","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamaoncol.2019.0130","article-title":"Hyperprogression-immunotherapy-related phenomenon vs intrinsic natural history of cancer","volume":"5","author":"Pearson","year":"2019","journal-title":"JAMA Oncol"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364320300175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364320300175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:35:19Z","timestamp":1762986919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364320300175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S2666364320300175"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2020.100017","relation":{},"ISSN":["2666-3643"],"issn-type":[{"type":"print","value":"2666-3643"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2020.100017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100017"}}